These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30593627)

  • 21. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
    Singal AG; Rich NE; Mehta N; Branch AD; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Ioannou GN; Huang A; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Kagan S; Gopal P; Wong R; Parikh ND; Murphy CC
    Gastroenterology; 2019 Nov; 157(5):1253-1263.e2. PubMed ID: 31374215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication.
    Ogawa E; Toyoda H; Iio E; Jun DW; Huang CF; Enomoto M; Hsu YC; Haga H; Iwane S; Wong G; Lee DH; Tada T; Liu CH; Chuang WL; Hayashi J; Cheung R; Yasuda S; Tseng CH; Takahashi H; Tran S; Yeo YH; Henry L; Barnett SD; Nomura H; Nakamuta M; Dai CY; Huang JF; Yang HI; Lee MH; Jun MJ; Kao JH; Eguchi Y; Ueno Y; Tamori A; Furusyo N; Yu ML; Tanaka Y; Nguyen MH;
    Clin Infect Dis; 2020 Dec; 71(11):2840-2848. PubMed ID: 31777940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis.
    Huang P; Liu M; Zang F; Yao Y; Yue M; Wang J; Fan H; Zhuo L; Wu J; Xia X; Feng Y; Yu R
    Carcinogenesis; 2018 Dec; 39(12):1497-1505. PubMed ID: 30602007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication.
    Huang CF; Awad MH; Gal-Tanamy M; Yu ML
    Clin Mol Hepatol; 2024 Jul; 30(3):326-344. PubMed ID: 38665034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
    Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K;
    J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    Motoyama H; Tamori A; Kubo S; Uchida-Kobayashi S; Takemura S; Tanaka S; Ohfuji S; Teranishi Y; Kozuka R; Kawamura E; Hagihara A; Morikawa H; Enomoto M; Murakami Y; Kawada N
    PLoS One; 2018; 13(3):e0194163. PubMed ID: 29534101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. lnc-HOTAIR predicts hepatocellular carcinoma in chronic hepatitis C genotype 4 following direct-acting antivirals therapy.
    El-Khazragy N; Elshimy AA; Hassan SS; Shaaban MH; Bayoumi AH; El Magdoub HM; Ghozy S; Gaballah A; Aboelhussein MM; Abou Gabal HH; Bannunah AM; Mansy AE
    Mol Carcinog; 2020 Dec; 59(12):1382-1391. PubMed ID: 33074585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma.
    Kamp WM; Sellers CM; Stein S; Lim JK; Kim HS
    J Vasc Interv Radiol; 2020 Jun; 31(6):953-960. PubMed ID: 32376182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection.
    Hayes CN; Zhang P; Zhang Y; Chayama K
    Viruses; 2018 Sep; 10(10):. PubMed ID: 30274202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hepatitis C virus infection and hepatocarcinogenesis].
    Berta E; Egresi A; Bacsárdi A; Gáspár Z; Lengyel G; Hagymási K
    Orv Hetil; 2019 Jun; 160(22):846-853. PubMed ID: 31131608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.
    Cabibbo G; Petta S; Calvaruso V; Cacciola I; Cannavò MR; Madonia S; Distefano M; Larocca L; Prestileo T; Tinè F; Bertino G; Giannitrapani L; Benanti F; Licata A; Scalisi I; Mazzola G; Cartabellotta F; Alessi N; Barbàra M; Russello M; Scifo G; Squadrito G; Raimondo G; Craxì A; Di Marco V; Cammà C;
    Aliment Pharmacol Ther; 2017 Oct; 46(7):688-695. PubMed ID: 28791711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma.
    Chinchilla-López P; Qi X; Yoshida EM; Méndez-Sánchez N
    Ann Hepatol; 2017; 16(3):328-330. PubMed ID: 28425400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy.
    Li H; Huang MH; Jiang JD; Peng ZG
    World J Gastroenterol; 2018 Dec; 24(47):5297-5311. PubMed ID: 30598575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic scars in regulatory T cells are retained after successful treatment of chronic hepatitis C with direct-acting antivirals.
    Kim SY; Koh JY; Lee DH; Kim HD; Choi SJ; Ko YY; Lee HS; Lee JS; Choi IA; Lee EY; Jeong HW; Jung MK; Park SH; Park JY; Kim W; Shin EC
    J Hepatol; 2024 Nov; 81(5):806-818. PubMed ID: 38879170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA.
    Hosui A; Tanimoto T; Okahara T; Ashida M; Ohnishi K; Wakahara Y; Kusumoto Y; Yamaguchi T; Sueyoshi Y; Hirao M; Yamada T; Hiramatsu N
    Hepatol Commun; 2021 Dec; 5(12):2001-2008. PubMed ID: 34752016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The impact of direct-acting antiviral therapy on the diagnosis of hepatitis-C virus-associated hepatocellular carcinoma].
    Takahashi A; Shima T; Kinoshita N; Yano K; Ueno T; Nishiwaki M; Yamamoto Y; Oya H; Amano I; Matsumoto J; Mitsumoto Y; Tanaka I; Sakai K; Sawai N; Mizuno C; Mizuno M; Itoh Y; Okanoue T
    Nihon Shokakibyo Gakkai Zasshi; 2018; 115(2):184-194. PubMed ID: 29459562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.